473P Phase I Study of GFH018, a Small Molecular TGF-βRI Inhibitor, in Patients (pts) with Advanced Solid Tumors

Y. Guo,W. Zishu,H. Zhou,H. Pan,W. Han,Y. Deng,Y. Zhang,H. Ren,H. Zhang,S. Wang,J. Li

DOI: https://doi.org/10.1016/j.annonc.2022.07.601

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:TGF-β signaling pathway activation promotes tumor metastasis and progression, mediates epithelial-mesenchymal transmission (EMT) suppressing immunosurveillance in advanced tumors. GFH018, a novel small molecule that inhibits TGF-βRI kinase, blocks TGF-β signaling transduction thus inhibits tumor progression. In preclinical models, GFH018 showed significant anti-tumor activity as monotherapy and in combination with an anti-PD-1 antibody. This phase I study will assess the safety, pharmacokinetics (PK), and preliminary efficacy of GFH018 monotherapy in pts with advanced solid tumors. This is an open-label, multicenter study comprising of a modified 3 + 3 dose escalation part followed by an expansion part. The starting dose was 5 mg and up to 8 cohorts were planned. Eligible pts with advanced solid tumors failed to standard therapies were administrated with GFH018 BID, 14d on/14d off in 28-day cycles. AEs were graded per NCI-CTCAE v5.0. PK analysis was performed using a non-compartmental method. Efficacy was evaluated per RECIST 1.1. As of Jan 25, 2022, 39 pts (5 mg [n=4]; 10 mg [n=3]; 20mg [n=4]; 30 mg [n=7]; 40, 50 mg [n=4 each]; 65 mg [n=6] and 85 mg [n=7]) were sequentially enrolled in the dose escalation part. The median lines of prior therapy were ≥ 3. No DLT was observed and the MTD was not reached. No pts discontinued due to AE. 35 pts (89.7%) had at least one related AE and 2 (5.1%) experienced ≥ grade (G) 3 related AE. The most common related AEs (all G/≥G3) were proteinuria (28.2%/2.6%), AST increased (15.4%/0), ALT increased (12.8%/0), anemia (12.8%/0), lymphocyte count decreased (10.3%/2.6%), ALP increased (10.3%/0), and LDH increased (10.3%/0). PK of GFH018 was linear and dose-independent with mean half-life in the range of 3.11 h- 8.30 h. Accumulation in PK exposure was limited post multiple dosing. Of 24 evaluable pts, 5 achieved stable disease (SD). A pt with thymic carcinoma receiving 50 mg achieved a durable SD with tumor shrinkage (maximum lesion decreased by 18.4%) and has stayed on treatment for 185 days as of the data cut-off date. GFH018 shows a favorable safety profile and is now being tested in combination with an anti-PD-1 antibody in patients with advanced malignancies. Further studies are warranted.